01—Abstract
Summary
Summary of the 10-Q filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported its quarterly results for the period ended September 30, 2025 in this Form 10-Q.
Total revenues, net were $120.7 milliona for the three months ended September 30, 2025, up from $2.7 million a year earlier, and $347.9 million for the nine months, up from $216.0 million. Net product revenue from Attruby was $108.1 million for the quarter and $216.4 million for the nine months. Net loss was $184.9 million for the quarter and $538.3 million for the nine months, compared with $164.3 million and $276.0 million in the prior-year periods.
Net loss attributable to common stockholders was $532.1 millionb for the nine months, or $(2.79) per share. The balance sheet shows cash, cash equivalents and marketable securities of $645.9 million as of September 30, 2025, compared with $681.1 million at December 31, 2024. Total liabilities were $2.92 billion against total assets of $998.3 million, resulting in a total stockholders' deficit of $1.92 billion.
The company issued $575.0 millionc of 1.75% convertible senior notes due 2031 in February 2025 and fully repaid its $450.0 million term loan, and it received $300.0 million from a royalty purchase agreement in June 2025. Deferred royalty obligations, net, stood at $836.1 million. Net cash used in operating activities was $389.5 million for the nine months.
Management states that existing cash, cash equivalents and marketable securities are expected to fund operations for at least the next 12 months. The filing describes ongoing restructuring charges of $8.8 milliond for the quarter, a noncash interest expense of $36.4 million on deferred royalty obligations, and a share repurchase of 1,405,411 shares for $48.3 million in February 2025. Management notes that it expects to continue incurring operating and net losses for at least the next several years.
02—Key points
Key Highlights
- Net product revenue from Attruby reached $108.1 million in the third quarter and $216.4 million for the nine months ended September 30, 2025, following FDA approval in November 2024.
- Total revenues, net were $120.7 million for the quarter, versus $2.7 million a year earlier, and $347.9 million for the nine months, versus $216.0 million.
- Net loss was $184.9 million for the quarter and $538.3 million for the nine months; net loss per share attributable to common stockholders was $(2.79) for the nine months.
- Cash, cash equivalents and marketable securities totaled $645.9 million at September 30, 2025, down from $681.1 million in cash and cash equivalents at December 31, 2024.
- Total stockholders' deficit widened to $(1.92) billion, with total liabilities of $2.92 billion against total assets of $998.3 million.
- In 2025 the company issued $575.0 million of 1.75% convertible notes due 2031, fully repaid its $450.0 million term loan, and received $300.0 million under a royalty purchase agreement.
- Net cash used in operating activities was $389.5 million for the nine months ended September 30, 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 29, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $120.70M$2.73M | +4318.0% |
| Cost of Revenue | $6.56M$598K | +997.5% |
| Gross Profit | $114.14M$2.13M | +5248.5% |
| R&D Expenses | $112.87M$120.44M | −6.3% |
| SG&A Expenses | $137.62M$68.82M | +100.0% |
| Operating Expenses | $265.90M$194.48M | +36.7% |
| Operating Income | -$145.20M-$191.75M | +24.3% |
| Net Income | -$182.74M-$162.04M | −12.8% |
| EPS (Basic) | $-0.95$-0.86 | −10.5% |
| EPS (Diluted) | $-0.95$-0.86 | −10.5% |
| Shares Outstanding (Basic) | 191.85M188.51M | +1.8% |
| Shares Outstanding (Diluted) | 191.85M188.51M | +1.8% |
05—Questions
Frequently Asked Questions
How much revenue did BridgeBio generate from Attruby and how is revenue trending?
Net product revenue from Attruby was $108.1 million for the three months and $216.4 million for the nine months ended September 30, 2025. Total revenues, net were $120.7 million for the quarter and $347.9 million for the nine months, compared with $2.7 million and $216.0 million in the same periods of 2024. License and services revenue for the nine months decreased to $125.4 million from $216.0 million, mainly because 2024 included upfront license fees recognized under the Bayer and Kyowa Kirin agreements.
What is the company's cash position and how long will it last?
BridgeBio had cash, cash equivalents and marketable securities of $645.9 million as of September 30, 2025. Management expects these resources to fund operations for at least the next 12 months from the filing date, based on current operating plans and forecasts, while noting that it may need additional funding sooner if plans or market conditions change.
How much debt and royalty financing does the company carry?
As of September 30, 2025, the company had convertible notes with principal of $575.0 million due 2031, $747.5 million due 2029 and $550.0 million due 2027. Deferred royalty obligations, net, were $836.1 million, including the Funding Agreement and the Royalty Purchase Agreement, which the filing says are accounted for as debt-like instruments.
Why did net loss increase and what drove operating expenses?
Selling, general and administrative expenses rose to $373.1 million for the nine months from $194.1 million, largely due to investments supporting the commercial launch of Attruby. Noncash interest expense on deferred royalty obligations was $86.5 million for the nine months, a new expense line in 2025. Research and development expenses fell to $335.5 million for the nine months from $376.1 million, reflecting reprioritization of programs.
Did the company repurchase shares or issue new equity in 2025?
In February 2025, the company repurchased 1,405,411 shares of common stock for approximately $48.3 million, concurrent with the closing of the 2031 notes offering. The filing reports no unregistered equity sales and no issuer repurchases in the third quarter of 2025. Common shares outstanding were 192,633,286 as of September 30, 2025.
06—Continue